Just over a year ago, soon after the dramatic exit of Francis deSouza as Illumina’s CEO, the company announced that it had appointed a new leader, Jacob Thaysen, PhD. The initial reactions were mixed. Thaysen had held multiple roles in the life sciences, most recently at Agilent Technologies. But despite his experience in the life sciences business, he was unknown to many in the genomics world. GEN reached out for an interview when he first took over, but Illumina declined the invitation. A lot has changed over the past year. Last November, GEN secured an interview with Thaysen at the annual meeting of the American Society for Human Genetics (ASHG), which was held in Denver, CO. He described how the past year has been, why he took the job in the first place, and what he is looking forward to doing in the future.
This interview has been edited for…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
